🇺🇸 FDA
Patent

US 6685941

Methods of treating autoimmune disease via CTLA-4Ig

expired A61KA61K2039/505A61K2239/31

Quick answer

US patent 6685941 (Methods of treating autoimmune disease via CTLA-4Ig) held by United States of America as represented by the Secretary of the Air Force expires Mon Jan 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
United States of America as represented by the Secretary of the Air Force
Grant date
Tue Feb 03 2004 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K2039/505, A61K2239/31, A61K2239/38, A61K2239/48